{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:54:54Z","timestamp":1761893694148},"reference-count":43,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Von Willebrand disease (vWD) is a frequent inherited disorder of hemostasis that affects both sexes. Two abnormalities are characteristic of the disease, which is caused by a deficiency or a defect in the multimeric glycoprotein called von Willebrand factor: low platelet adhesion to injured blood vessels and defective intrinsic coagulation owing to low plasma levels of factor VIII. There are 2 main options available for the treatment of spontaneous bleeding episodes and for bleeding prophylaxis: desmopressin and transfusional therapy with plasma products. Desmopressin is the treatment of choice for most patients with type 1 vWD, who account for approximately 70% to 80% of cases. This nontransfusional hemostatic agent raises endogenous factor VIII and von Willebrand factor 3 to 5 times and thereby corrects both the intrinsic coagulation and the primary hemostasis defects. In patients with the more severe type 3 and in most patients with type 2 disease, desmopressin is ineffective or is contraindicated and it is usually necessary to resort to plasma concentrates containing both factor VIII and von Willebrand factor. Concentrates treated with virucidal methods should be preferred to cryoprecipitate because they are equally effective and are perceived as safer.<\/jats:p>","DOI":"10.1182\/blood.v97.7.1915","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T08:46:47Z","timestamp":1027759607000},"page":"1915-1919","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":123,"title":["How I treat patients with von Willebrand disease"],"prefix":"10.1182","volume":"97","author":[{"given":"Pier Mannuccio","family":"Mannucci","sequence":"first","affiliation":[{"name":"From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and the Department of Internal Medicine, IRCCS Maggiore Hospital, University of Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021217061182400_B1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-0037-1613992","article-title":"Impact, diagnosis and treatment of von Willebrand disease.","volume":"84","author":"Sadler","year":"2000","journal-title":"Thromb Haemost."},{"key":"2020021217061182400_B2","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1055\/s-0038-1642471","article-title":"A revised classification of von Willebrand disease.","volume":"71","author":"Sadler","year":"1994","journal-title":"Thromb Haemost."},{"key":"2020021217061182400_B3","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1046\/j.1365-2516.1998.440654.x","article-title":"Diagnosis of von Willebrand disease.","volume":"4","author":"Federici","year":"1998","journal-title":"Haemophilia."},{"key":"2020021217061182400_B4","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood.V90.7.2515","article-title":"Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years.","volume":"90","author":"Mannucci","year":"1997","journal-title":"Blood."},{"key":"2020021217061182400_B5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1172\/JCI9516","article-title":"Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP.","volume":"106","author":"Kaufmann","year":"2000","journal-title":"J Clin Invest."},{"key":"2020021217061182400_B6","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0140-6736(77)91197-7","article-title":"Deamino\u20138-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand disease.","volume":"1","author":"Mannucci","year":"1977","journal-title":"Lancet."},{"key":"2020021217061182400_B7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2141.1992.tb04598.x","article-title":"Consistency of responses to repeated DDAVP infusions in patients with von Willebrand disease and haemophilia A.","volume":"82","author":"Mannucci","year":"1992","journal-title":"Br J Haematol."},{"key":"2020021217061182400_B8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2141.1981.tb02789.x","article-title":"Response of factor VIII\/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand disease.","volume":"47","author":"Mannucci","year":"1981","journal-title":"Br J Haematol."},{"key":"2020021217061182400_B9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajh.2830310310","article-title":"Hyponatremia and seizures in young children given DDAVP.","volume":"31","author":"Smith","year":"1989","journal-title":"Am J Hematol."},{"key":"2020021217061182400_B10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJM198801143180215","article-title":"Myocardial infarction in a patient with hemophilia A treated with DDAVP.","volume":"318","author":"Bond","year":"1988","journal-title":"N Engl J Med."},{"key":"2020021217061182400_B11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/ajh.2830280115","article-title":"Thrombosis following desmopressin for uremic bleeding.","volume":"28","author":"Byrnes","year":"1988","journal-title":"Am J Hematol."},{"key":"2020021217061182400_B12","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.V66.4.796.796","article-title":"Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor.","volume":"66","author":"Mannucci","year":"1985","journal-title":"Blood."},{"key":"2020021217061182400_B13","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJM198310063091402","article-title":"Platelet aggregation induced by 1-des-amino-8-D-arginine vasopressin (DDAVP) in type II B von Willebrand disease.","volume":"309","author":"Holmberg","year":"1983","journal-title":"N Engl J Med."},{"key":"2020021217061182400_B14","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2141.1994.tb05127.x","article-title":"Biological effect of desmopressin in eight patients with type 2 N (\u2018Normandy\u2019) von Willebrand disease.","volume":"88","author":"Mazurier","year":"1994","journal-title":"Br J Haematol."},{"key":"2020021217061182400_B15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM199807233390407","article-title":"Hemostatic drugs.","volume":"339","author":"Mannucci","year":"1998","journal-title":"N Engl J Med."},{"key":"2020021217061182400_B16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood.V30.3.375.375","article-title":"Correction of the hemostatic defects in von Willebrand disease.","volume":"30","author":"Perkins","year":"1967","journal-title":"Blood."},{"key":"2020021217061182400_B17","first-page":"193","article-title":"Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease.","volume":"62","author":"Rodeghiero","year":"1992","journal-title":"Vox Sang."},{"key":"2020021217061182400_B18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1365-2516.1998.0040s3033.x","article-title":"Pharmacokinetics, efficacy and safety of Humate-P\u00ae in von Willebrand disease.","volume":"4","author":"Dobrokovska","year":"1998","journal-title":"Haemophilia."},{"key":"2020021217061182400_B19","first-page":"98b","article-title":"Treatment of von Willebrand's disease (vWD) with a high purity factor VIII concentrate: dissociation between correction of the bleeding time (BT), vWF multimer pattern, and treatment efficacy.","volume":"94(suppl 1)","author":"Mannucci","year":"1999","journal-title":"Blood"},{"key":"2020021217061182400_B20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF00319766","article-title":"The use of heat\u2013treat factor VIII concentrates in von Willebrand's disease.","volume":"50","author":"Kohler","year":"1985","journal-title":"Blut."},{"key":"2020021217061182400_B21","first-page":"228","article-title":"In vitro and in vivo characterization of a high-purity, solvent detergent treated factor VIII concentrate: evidence of its therapeutic efficacy in von Willebrand disease.","volume":"75","author":"Mazurier","year":"1990","journal-title":"Eur J Haematol."},{"key":"2020021217061182400_B22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1365-2141.1990.tb02654.x","article-title":"Clinical and laboratory evaluation of the treatment of von Willebrand's disease patients with heat-treated factor VIII concentrate (BPL 8Y).","volume":"75","author":"Pasi","year":"1990","journal-title":"Br J Haematol."},{"key":"2020021217061182400_B23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF01836069","article-title":"Pharmacokinetics and hemostatic effect of different factor VIII\/von Willebrand factor concentrates in von Willebrand's disease type III.","volume":"65","author":"Lethagen","year":"1992","journal-title":"Ann Hematol."},{"key":"2020021217061182400_B24","first-page":"173","article-title":"The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease.","volume":"71","author":"Hanna","year":"1994","journal-title":"Thromb Haemost."},{"key":"2020021217061182400_B25","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/s-0038-1649564","article-title":"Pharmacokinetics of monoclonally purified and recombinant factor VIII in patients with severe von Willebrand disease.","volume":"70","author":"Morfini","year":"1993","journal-title":"Thromb Haemost."},{"key":"2020021217061182400_B26","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1046\/j.1365-2141.1996.d01-1860.x","article-title":"Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 vWD): estimation of the rate of factor VIIIC synthesis.","volume":"94","author":"Menache","year":"1996","journal-title":"Br J Haematol."},{"key":"2020021217061182400_B27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1365-2516.1998.0040s3048.x","article-title":"Clinical management of patients with von Willebrand disease with a VHP VWF concentrate: the French experience.","volume":"4","author":"Goudemand","year":"1998","journal-title":"Haemophilia."},{"key":"2020021217061182400_B28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2516.1998.0040s3001.x","article-title":"Summary of a workshop on potency and dosage of von Willebrand factor concentrates.","volume":"4","author":"Chang","year":"1998","journal-title":"Haemophilia."},{"key":"2020021217061182400_B29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ajh.2830450303","article-title":"Von Wllebrand disease: use of collagen binding assay provides potential improvement in laboratory monitoring of desmopressin (DDAVP) therapy.","volume":"45","author":"Favaloro","year":"1994","journal-title":"Am J Hematol."},{"key":"2020021217061182400_B30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2516.1998.0040s3015.x","article-title":"The determination of von Willebrand factor activity by collagen binding assay.","volume":"4","author":"Siekmann","year":"1998","journal-title":"Haemophilia."},{"key":"2020021217061182400_B31","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1182\/blood.V79.12.3130.bloodjournal79123130","article-title":"Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial.","volume":"79","author":"Mannucci","year":"1992","journal-title":"Blood."},{"key":"2020021217061182400_B32","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1182\/blood.V83.10.3018.3018","article-title":"Proteolysis of von Willebrand factor in therapeutic plasma concentrates.","volume":"83","author":"Mannucci","year":"1994","journal-title":"Blood."},{"key":"2020021217061182400_B33","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood.V77.9.1901.1901","article-title":"Hemostatic effect of normal platelet transfusion in severe von Willebrand disease.","volume":"77","author":"Castillo","year":"1991","journal-title":"Blood."},{"key":"2020021217061182400_B34","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1046\/j.1537-2995.1997.37897424399.x","article-title":"Hemostasis in patients with severe von Willebrand disease improves after normal platelet transfusion and normalizes with further correction of the plasma defect.","volume":"37","author":"Castillo","year":"1987","journal-title":"Transfusion."},{"key":"2020021217061182400_B35","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1046\/j.1365-2141.2000.02507.x","article-title":"Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease.","volume":"111","author":"Lak","year":"2000","journal-title":"Br J Haematol."},{"key":"2020021217061182400_B36","first-page":"282","article-title":"Pregnancy in women with different types of von Willebrand disease.","volume":"68","author":"Conti","year":"1986","journal-title":"Obstet Gynecol."},{"key":"2020021217061182400_B37","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2141.1990.tb02621.x","article-title":"Spontaneous platelet aggregation during pregnancy in a patient with vWD type II B can be blocked by monoclonal antibodies to both platelet glycoproteins Ib and IIb\/IIIa.","volume":"75","author":"Pareti","year":"1990","journal-title":"Br J Haematol."},{"key":"2020021217061182400_B38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-1-4613-0331-2_7","article-title":"Antibodies to von Willebrand factor in von Willebrand disease.","volume-title":"Inhibitors to coagulation factor in the 1990s.","author":"Mannucci","year":"1995"},{"key":"2020021217061182400_B39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1749-6632.1987.tb30987.x","article-title":"Factor VIII inhibitors: etiology, characterization, natural history, and management.","volume":"509","author":"Lusher","year":"1987","journal-title":"Ann N Y Acad Sci."},{"key":"2020021217061182400_B40","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood.V71.2.344.344","article-title":"The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study, II: observations on the initial development of factor VIII:C inhibitors.","volume":"71","author":"McMillan","year":"1988","journal-title":"Blood."},{"key":"2020021217061182400_B41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood.V57.1.25.25","article-title":"Precipitating antibodies to FVIII\/von Willebrand factor in von Willebrand disease: effects on replacement therapy.","volume":"57","author":"Mannucci","year":"1981","journal-title":"Blood."},{"key":"2020021217061182400_B42","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1600-0609.1987.tb01458.x","article-title":"Life-threatening reaction to FVIII concentrate in a patient with severe vWD and alloantibodies to vWF.","volume":"39","author":"Mannucci","year":"1987","journal-title":"Eur J Haematol."},{"key":"2020021217061182400_B43","first-page":"348","article-title":"Posttransfusion anaphylactic reaction in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor.","volume":"125","author":"Bergamaschini","year":"1995","journal-title":"J Lab Clin Med."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/97\/7\/1915\/1671780\/h8070101915.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/97\/7\/1915\/1671780\/h8070101915.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T17:50:21Z","timestamp":1581529821000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/97\/7\/1915\/53343\/How-I-treat-patients-with-von-Willebrand-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4,1]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2001,4,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v97.7.1915","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2001,4,1]]}}}